Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MRNS Relative to the S&P 500

MRNS Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Marinus Pharmaceuticals, Inc. (NASD:MRNS) seasonal charts above shows that a Buy Date of November 16 and a Sell Date of February 15 has resulted in a geometric average return of 19.41% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 62.77% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

To download MRNS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MRNS